JC Partners files for regulatory review to acquire KDB Life Insurance Financial watchdog expected to complete review process by August
Translated by Ryu Ho-joung 공개 2021-06-22 08:25:50
이 기사는 2021년 06월 22일 08:15 thebell 에 표출된 기사입니다.
The last hurdle for JC Partners to acquire a troubled South Korean life insurance company is likely to clear in two months as the country’s financial watchdog begins regulatory review.The Seoul-based private equity firm filed paperwork with the Financial Supervisory Service (FSS) on Thursday to kick off a process to examine whether it is eligible to become the largest shareholder of KDB Life Insurance, industry sources said.
The regulatory review comes six months after JC Partners signed a deal to buy some 92% of the insurance company from the state-controlled Korea Development Bank in December. The evaluation process is expected to take around 60 days to complete, with a final decision likely to be made in August.
JC Partners’ acquisition of KDB Insurance has been under preliminary review for the past few months, through which the private equity firm produced a final draft for review by the FSS.
JC Partners is said to have paid careful attention to the composition of limited partners to get approval from the financial authorities, which are stricter toward a private equity firm’s acquisition of a financial services company.
JC Partners has completed financing for the acquisition. 200 billion won ($176.4 million), which was raised from Woori Bank and KDB, will be paid to purchase shares from existing shareholders. The firm will also inject 150 billion won into the insurance company.
It has reportedly yet to be determined whether JC Partners will invest more money in KDB Life Insurance to boost its capital base. An additional capital injection is likely to be decided depending on how the company will fare under JC Partners’ ownership.
JC Partners, if it gets the green light from the FSS, will likely focus on improving the company’s capital adequacy level. KDB Life Insurance had a risk-based capital ratio of 187% at the end of March, far below the industry average of 273.2%. (Reporting by Ar-rum Rho)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 코인원, 이용규 CPO 영입…신규 서비스 출시 속도
- [코스닥 코스메틱 리뉴얼]마스크팩 잘나가던 지피클럽, 색조화장 '코디 인수'
- [K-배터리 밸류업 리포트]'오너 경영체제' 원준, 승계작업 '언제쯤'
- [thebell note]제약바이오는 다이어트 중
- [바이오텍 유증·메자닌 승부수]브릿지바이오, 유무상증자에 '대표 지분 블록딜' 왜?
- [제일약품의 온코닉테라퓨틱스 첫 '신약']성장성·사업성 갖춘 IPO 기대주 '밸류업' 이유 더 있다
- [코스닥 리빌딩 리포트]'조달 지연' 비투엔, 불성실공시법인 지정 가능성은
- [Board Index/네이버]사외이사 정보제공 '정조준'…교육도 대폭 늘려
- "35년 영업맨, 상장 후 글로벌 시장 노린다"
- [아시아나 화물사업부 M&A]LOC 낸 에어인천·이스타, LOI 낸 에어프레미아